Skip to content

Study · Randomized controlled trial · n = 170 · 2011

5 results

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, Takei H, Yanagita Y, Noguchi S

Breast cancer research and treatment8 Jan 2011Cited by 44 (Europe PMC)

PMID21221770 (opens in a new tab)DOI10.1007/s10549-010-1332-y (opens in a new tab)PepBankPUB-21221770
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with early breast cancer, goserelin 10.8 mg was non-inferior to 3.6 mg for estradiol AUC (ratio 0.974; 95% CI 0.80, 1.19).

    In plain wordsIn women with breast cancer, three-monthly goserelin 10.8 mg met the non-inferiority criterion versus monthly 3.6 mg for estradiol suppression.

    Peptide
    Goserelin
    Outcome
    Direction not reportedEstradiol AUC over 24 weeks
    Study

    n = 170

    Comparator
    Goserelin 3.6 mg monthly
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10.8 mg every 3 months · 24 weeksAs given in this study (human).

    Measurements

    Estradiol AUC
    18.32 pg/ml·week
    Goserelin 10.8 mg
    Estradiol AUC
    18.95 pg/ml·week
    Goserelin 3.6 mg
    AUC ratio
    0.974
    95% confidence interval 0.80, 1.19

    Source sentences

    Summary
    Mean AUCs for E(2) were similar between treatment groups (18.32 and 18.95 pg/ml·week for goserelin 10.8 and 3.6 mg, respectively).
    4 context sentences
    Summary · context
    AUC ratio was 0.974 (95% confidence interval, 0.80, 1.19), indicating non-inferiority for goserelin 10.8 mg.
    Summary · context
    This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer.
    Summary · context
    This was a multicenter, open-label, randomized study.
    Summary · context
    In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84).
  2. 02HumanRandomized controlled trialSafety outcome

    In women with early breast cancer, goserelin regimens showed no clinically important differences in safety and tolerability.

    In plain wordsIn women with breast cancer, safety and tolerability showed no clinically important differences between the goserelin regimens.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSafety and tolerability
    Study

    n = 170

    Comparator
    Goserelin 3.6 mg monthly
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    10.8 mg every 3 monthsAs given in this study (human).

    Source sentences

    Summary
    No clinically important differences in safety and tolerability were observed between the two groups.
    3 context sentences
    Summary · context
    This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer.
    Summary · context
    This was a multicenter, open-label, randomized study.
    Summary · context
    In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84).
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with early breast cancer, estradiol remained suppressed throughout the study with both goserelin regimens.

    In plain wordsIn women with breast cancer, estradiol remained suppressed with both goserelin regimens.

    Peptide
    Goserelin
    Outcome
    DecreaseEstradiol suppression
    Study

    n = 170

    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum E(2) and FSH remained suppressed throughout the study and no patient experienced menses after week 16.
    3 context sentences
    Summary · context
    This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer.
    Summary · context
    This was a multicenter, open-label, randomized study.
    Summary · context
    In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84).
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with early breast cancer, FSH remained suppressed throughout the study with both goserelin regimens.

    In plain wordsIn women with breast cancer, FSH remained suppressed with both goserelin regimens.

    Peptide
    Goserelin
    Outcome
    DecreaseFSH suppression
    Study

    n = 170

    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum E(2) and FSH remained suppressed throughout the study and no patient experienced menses after week 16.
    3 context sentences
    Summary · context
    This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer.
    Summary · context
    This was a multicenter, open-label, randomized study.
    Summary · context
    In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84).
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with early breast cancer receiving either goserelin regimen, no patient experienced menses after week 16.

    In plain wordsIn women with breast cancer receiving either goserelin regimen, no patient menstruated after week 16.

    Peptide
    Goserelin
    Outcome
    Direction not reportedMenstruation
    Study

    n = 170

    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum E(2) and FSH remained suppressed throughout the study and no patient experienced menses after week 16.
    3 context sentences
    Summary · context
    This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer.
    Summary · context
    This was a multicenter, open-label, randomized study.
    Summary · context
    In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.